Necrotising Enterocolitis Market

Rising incidence for NEC is driving the market growth

The market CAGR is being driven by the rising occurrence of necrotizing enterocolitis. When the intestinal inflammation known as necrotizing enterocolitis, which typically affects the colon, is not properly treated, it can be fatal. A hole forms in the intestinal wall as a result of necrotizing enterocolitis, which only affects the intestinal lining. Since the break in the intestinal wall allows the normal bacteria in the gut to spill into the belly, other surrounding body organs become infected. A medical emergency has been created by the infection's rapid progression.

The most prevalent time for NEC to afflict newborns is 3 to 12 days following birth. Lethargy, fever, apnea, poor tolerance to emotions, bloody stool, stomach redness, and others are among the signs of NEC. Antibiotics, vasopressors, glucocorticoids, and opioid analgesics are some of the most popular treatments for NEC. According to an NCBI publication, NEC is the most common cause of newborn gastrointestinal infection-related death, accounting for 1-3 occurrences per 1000 live births annually in North America.

This growing patient population has a variety of symptoms that call for appropriate treatment; as a result, it is anticipated that the market will experience profitable expansion.

The market expansion is predicted to be fueled by the expanded range of treatment options available for NEC. Increasing populations and per capita incomes have changed people's needs, which is fueling the  market's revenue growth. People now prefer more cutting-edge, scientifically complex treatments and pharmaceuticals. The government's improved regulatory framework for the development of new antibiotics and therapies to minimize the effects of necrotizing enterocolitis in newborn babies, as well as the accessibility of treatments and medications for the treatment of necrotizing enterocolitis, are also expected to significantly propel revenue growth of the necrotizing enterocolitis market over the forecast period.

The Global Necrotising Enterocolitis Market Industry is poised for substantial growth, with projections indicating a market value of 9.81 USD Billion by 2035. This growth is underpinned by various factors, including advancements in medical technology, increased awareness, and government support. The compound annual growth rate of 5.51% from 2025 to 2035 suggests a robust expansion trajectory. As healthcare systems worldwide continue to prioritize neonatal health, the demand for effective treatments and interventions for necrotising enterocolitis is likely to rise. This positive outlook reflects the industry's potential to address the challenges associated with this serious condition.

There is a growing awareness regarding necrotising enterocolitis among healthcare professionals and parents, which is positively influencing the Global Necrotising Enterocolitis Market Industry. Educational initiatives aimed at informing caregivers about the signs, symptoms, and risk factors associated with this condition are crucial. Enhanced understanding leads to earlier diagnosis and intervention, which can significantly improve survival rates. As awareness campaigns proliferate, the demand for diagnostic and therapeutic solutions is expected to rise. This trend is reflected in the anticipated market growth, with projections indicating a value of 9.81 USD Billion by 2035, highlighting the impact of education on healthcare outcomes.

Technological advancements in neonatal care are playing a crucial role in the Global Necrotising Enterocolitis Market Industry. Innovations such as improved imaging techniques, minimally invasive surgical procedures, and enhanced nutritional support systems are contributing to better outcomes for affected infants. These advancements not only facilitate early diagnosis but also enhance treatment efficacy, thereby reducing mortality rates associated with necrotising enterocolitis. As healthcare providers adopt these technologies, the market is likely to expand, with a projected compound annual growth rate of 5.51% from 2025 to 2035. This growth trajectory underscores the importance of continuous innovation in improving neonatal health.

Government initiatives aimed at improving neonatal health are significantly impacting the Global Necrotising Enterocolitis Market Industry. Various countries are implementing policies to enhance healthcare infrastructure, particularly in neonatal intensive care units. Increased funding for research and development of new treatments and technologies is also evident. These initiatives not only aim to reduce the incidence of necrotising enterocolitis but also to improve overall neonatal care. As governments prioritize infant health, the market is likely to benefit from increased investments, fostering innovation and expanding access to effective treatments. This supportive environment is crucial for achieving sustainable growth in the industry.

The Global Necrotising Enterocolitis Market Industry is witnessing an increase in demand due to the rising incidence of premature births. According to health statistics, approximately 15 million infants are born prematurely each year, which significantly elevates the risk of developing necrotising enterocolitis. This condition predominantly affects preterm infants, leading to a higher need for specialized medical interventions and treatments. As the global population continues to grow, the number of premature births is expected to rise, thereby driving the market's growth. The projected market value of 5.44 USD Billion in 2024 reflects this increasing demand for effective management and treatment options.

The demand for specialized nutritional products designed for preterm infants is a significant driver of the Global Necrotising Enterocolitis Market Industry. Nutritional support plays a vital role in the prevention and management of necrotising enterocolitis, as appropriate feeding practices can mitigate risks. The market for these nutritional products is expanding, driven by the need for tailored solutions that cater to the unique requirements of vulnerable infants. As healthcare providers increasingly recognize the importance of nutrition in neonatal care, the market is expected to grow substantially, contributing to the overall projected market value of 5.44 USD Billion in 2024.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American necrotising enterocolitis market area will dominate this market because necrotizing enterocolitis is becoming more common and because disease detection technology is advanced. Necrotizing enterocolitis, with 1-3 cases per 1,000 births observed in North America each year, is the leading cause of gastrointestinal infection-related infant death, according to the National Centre for Biotechnology Information (NCBI). The expanding patient base has a variety of symptoms that call for the right care, which is expected to fuel market growth.

The North American market is also being driven by an increase in healthcare spending. Over the course of the projected period, these factors are also anticipated to help the region gain market share.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 NECROTISING ENTEROCOLITIS MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe necrotising enterocolitis market accounts for the second-largest market share as the majority of the research and development efforts are being made in industrialized nations like France, Germany, Denmark, Belgium, etc., for the creation of a long-lasting remedy for the infection. Additionally, these nations have seen a significant expansion of the necrotizing enterocolitis market as a result of the quick advancements in technology. Further, the German necrotising enterocolitis market held the largest market share, and the UK necrotising enterocolitis market was the fastest growing market in the European region

The Asia-Pacific Necrotising enterocolitis Market is expected to grow at the fastest CAGR from 2023 to 2032. Numerous nations, including China, Japan, Korea, and India, are thought to produce the majority of the market's earnings from necrotizing enterocolitis. Data on necrotizing enterocolitis show that the majority of people in these nations are infants and newborns, who are more prone to developing necrotizing enterocolitis. Additionally, the region's healthcare market is experiencing revenue growth as a result of the shift in people's health consciousness and the modernization of healthcare facilities.

Moreover, China’s necrotising enterocolitis market held the largest market share, and the Indian necrotising enterocolitis market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the necrotising enterocolitis market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, necrotising enterocolitis industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  necrotising enterocolitis industry to benefit clients and increase the market sector. In recent years, the necrotising enterocolitis industry has offered some of the most significant advantages to market.

Major players in the necrotising enterocolitis market attempting to increase market demand by investing in research and development operations include Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson, and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company, Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), and GlaxoSmithKline Plc (UK).

Bristol-Myers Squibb Co. (BMS) is a specialist biopharmaceutical business that develops, manufactures, distributes, and sells drugs and related medical supplies to people with serious conditions. Cancer, cardiovascular, immunology, and fibrotic therapeutic projects are its main areas of interest. The business provides its goods to wholesalers, retail pharmacies, health care workers, hospitals, and governmental organisations all around the world. Products from BMS are available in the US, Europe, and Japan. The organisation conducts research with a focus on the discovery and development of brand-new medications that treat severe illnesses in regions with a high unmet medical need.

Pharmaceuticals of all kinds are discovered, developed, produced, and sold by Astellas Pharma Inc (Astellas). Marketed treatments for the treatment of a variety of urological disorders, cancer, nephrology, infectious diseases, metabolic diseases, immunodeficiency diseases, and transplantation are included in the company's product portfolio. Its pipeline includes drug candidates for the treatment of various diseases, including acute myeloid leukaemia (AML), urothelial cancer, gastric cancer, gastroesophageal junction cancer, anaemia linked to chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis, and non-dialysis patients.